3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients

3D-PREDICT Trial Tests Kiyatec’s Predictor of Treatment Responses in Ovarian Cancer Patients
An ongoing observational registry study is evaluating Kiyatec's novel technology, in which a patient’s own tumor tissue is cultured in a lab dish and exposed to different therapies as a means to predict treatment response in women with ovarian cancer. The 3D-PREDICT trial (NCT03561207) is studying the company’s patient-specific Ex Vivo 3D Cell Culture (EV3D) assay as a predictor of chemotherapy responses in ovarian cancer patients whose disease is newly diagnosed or recurred after prior treatment. The Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) is the most recent institution joining this observational study, the company announced in a press release. Enrollment is ongoing; more information on contacts and locations is available here. “Ovarian cancer patients and clinicians do not have the luxury of time to experiment with drug therapies they don’t know will work, so we developed our investigational ovarian cancer drug response profile to help optimize therapeutic decision-making over the course of the disease,” said Matthew Gevaert, CEO of Kiyatec. “We are delighted to
Subscribe or to access all post and page content.